Biochemical Selectivity Profiling for RNA Helicase Inhibitors
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods lack effective and selective inhibitors for RNA helicases, which are crucial for cancer treatment due to their unique dependency in cancer cells, but existing assays and tools are insufficient for identifying clinical-grade inhibitors.
Innovation Solution
Development of methods and compositions for characterizing and identifying selective inhibitors of RNA helicases and splicing regulators using biochemical platforms that include purified RNA helicase proteins and optimized assays to monitor their activity, ensuring selectivity across the RNA helicase family and counter-selectivity against non-target helicases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If selective inhibitors for RNA helicases are developed, then cancer cell dependency is addressed, but lack of assays and tools prevents identification of clinical-grade inhibitors
Solution Approach 1:
The patent segments the RNA helicase family into multiple individual targets, creating separate biochemical assays for each helicase member. This segmentation allows systematic evaluation of compound selectivity across the family by testing against purified proteins from each segment individually, resolving the contradiction between achieving selectivity and managing assay complexity.
Solution Approach 2:
The patent performs preliminary actions by expressing and purifying RNA helicase proteins before conducting inhibitor screens. This preliminary preparation of high-quality purified proteins enables subsequent selective inhibition studies to be conducted with confidence, addressing the reliability issue while establishing a standardized platform that manages complexity through pre-established protocols.
2Object-affected harmful factors
If inhibitors are designed to target specific RNA helicases, then cancer cell survival is compromised, but without selective assays, off-target effects on normal cells cannot be avoided
Solution Approach 1:
The patent creates a universal biochemical platform that can assess selectivity across multiple RNA helicase targets simultaneously. This multi-functional platform uses standardized purified protein preparations and compatible assay conditions to evaluate compound selectivity against the entire helicase family, enabling precise measurement of off-target effects while maintaining broad applicability.
Solution Approach 2:
The patent replaces cellular-based screening mechanisms with purified protein-based biochemical assays. This substitution eliminates cellular complexity and background interference, allowing precise measurement of direct inhibitor-helicase interactions and enabling accurate assessment of selectivity without confounding cellular factors that would reduce measurement precision.
3Adaptability or versatility
If a biochemical platform with purified RNA helicase proteins is developed, then selectivity profiling is enabled, but resource requirements and assay optimization complexity increase
Solution Approach 1:
The patent systematically optimizes assay parameters including ATP concentration, magnesium levels, RNA substrate sequences, and incubation conditions for each purified helicase preparation. These parameter changes enable the biochemical platform to achieve high adaptability across different helicase members while establishing standardized protocols that simplify subsequent manufacturing and assay execution.
Solution Approach 2:
The patent employs self-service approaches by using recombinant expression systems to produce purified helicase proteins with inherent stability and activity. The purified proteins serve their own function as assay substrates without requiring additional cellular components, simplifying assay manufacture and enabling the platform to be self-sufficient while maintaining high versatility across the helicase family.
Data Source
AI summary
Embodiments of the disclosure concern identification of suitable inhibitors of components of RNA metabolism, including those involved with splicing, such as RNA helicases. The disclosure includes in vitro screens for small molecule inhibitors that are selective for a group of RNA helicases but that are counter-selective for another group of RNA helicases. In specific embodiments, the disclosure includes a system for inhibitor analysis that includes assay development and optimization that leads to feasible screening of the intended target(s) and continued counter-selection against undesirable targets throughout the process.